Subscribe To

Price Alert Latest News Economic Calendar News

XENE / Xenon Pharmaceuticals Inc. (XENE) Q4 2022 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Chris Kenney - CMO Chris Von Seggern - CCO Conference Call Participants Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Andrew Tsai - Jefferies Rudy Li - SVB Securities Laura Chico - Wedbush Rohit Bhasin - Needham & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call. I would now like to turn the call over to Sherry Aulin, CFO. Read More

Demo Live Account See Partner Details

Content Topics

Xenon

Pharmaceuticals

Inc

XENE

2022

Earnings

Call

xene

Transcript

Stock

Posted: Mar 1 2023, 22:10

Author Name: Seeking Alpha

XENE News

By GlobeNewsWire
November 1, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company

By GlobeNewsWire
September 14, 2023

Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical compan

By GlobeNewsWire
August 31, 2023

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company

By Seeking Alpha
August 13, 2023

Xenon Is Well-Funded Heading Into Key Readouts

Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health i

By Zacks Investment Research
August 11, 2023

Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectivenes

By Seeking Alpha
August 9, 2023

Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Morti

By Zacks Investment Research
August 9, 2023

Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates

Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares t

By GlobeNewsWire
June 6, 2023

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.